ライフサイエンスコーパス: treprostinil

1 [31%] sildenafil, and 233 [36%] subcutaneous treprostinil).

2 No serious adverse events were attributed to treprostinil.

3 rsening events in patients receiving inhaled treprostinil.

4 sence of atrial natriuretic peptide, NO, and treprostinil.

5 ipient mice were subcutaneously administered treprostinil (0.15 mg kg(-1) 8 h(-1)) for 10 days.

6 ents withdrew from the study prematurely (13 treprostinil, 10 placebo).

7 osentan received either 30 microg of inhaled treprostinil 4 times daily (n = 6) or 45 microg 4 times

8 The addition of inhaled treprostinil, a long-acting prostacyclin analog, might b

9 We tested the hypothesis that treprostinil, a prostacyclin analog approved for the tre

10 Treprostinil, a stable prostacyclin analogue with a half

11 e assigned in a 1:1 ratio to receive inhaled treprostinil, administered by means of an ultrasonic, pu

12 randomization, with 163 assigned to inhaled treprostinil and 163 to placebo.

13 human HSPCs, which had been pretreated with treprostinil and forskolin, enhanced survival of lethall

14 ostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosen

15 amic differences associated with intravenous treprostinil are clinically important requires longer fo

16 evaluated the safety and efficacy of inhaled treprostinil as add-on therapy to oral bosentan in patie

17 NT-proBNP levels from baseline with inhaled treprostinil as compared with an increase of 46% with pl

18 Borg score were maintained with intravenous treprostinil at Week 12 versus intravenous epoprostenol

19 results support the continuation of inhaled treprostinil despite the occurrence of disease progressi

20 rt that PGI(2) analogs (iloprost, cicaprost, treprostinil) differentially modulate the response of mu

21 The intravenous treprostinil dose was adjusted to minimize symptoms/side

22 In addition, iloprost and treprostinil enhanced BMP-induced phosphorylation of Sma

23 al of recipient mice was causally related to treprostinil-enhanced CXCR4-dependent migration of HSPCs

24 50 augmented atrial natriuretic peptide- and treprostinil-evoked pulmonary vascular relaxation in iso

25 The safety and efficacy of inhaled treprostinil for patients with this condition are unclea

26 e progression events occurred in the inhaled treprostinil group (89/163 patients, 55%) compared with

27 he least-squares mean difference between the treprostinil group and the placebo group in the change f

28 ening occurred in 37 patients (22.7%) in the treprostinil group as compared with 54 patients (33.1%)

29 disease progression component in the inhaled treprostinil group: 6-minute-walk distance decline (45 v

30 Fewer patients receiving inhaled treprostinil had multiple progression events compared wi

31 on due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, a

32 mptomatic on bosentan or sildenafil, inhaled treprostinil improves exercise capacity and quality of l

33 In these patients, treatment with inhaled treprostinil improves walking distance and respiratory s

34 assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) pa

35 epoprostenol, chronic subcutaneously infused treprostinil, inhaled iloprost, and oral beraprost.

36 Treprostinil inhibited phagocytosis, bacterial killing,

37 educed BMPR-II expression, we confirmed that treprostinil inhibited smooth muscle cell proliferation

38 valence between subcutaneous and intravenous treprostinil, intravenous treprostinil may have an overa

39 The prostacyclin analog treprostinil is also efficacious by subcutaneous infusio

40 from intravenous epoprostenol to intravenous treprostinil is safe and effective; whether the hemodyna

41 This trial suggests that inhaled treprostinil is safe, well tolerated, and associated wit

42 us and intravenous treprostinil, intravenous treprostinil may have an overall better risk-benefit pro

43 Rationale: The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-min

44 e effect of continued treatment with inhaled treprostinil on the frequency and impact of multiple dis

45 effects of iloprost, carbaprostacyclin, and treprostinil on the regulation of phagocytosis, bacteria

46 from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h.

47 the trough period, just before inhalation of treprostinil (p = 0.009).

48 Treprostinil, proposed to dilate by activating TASK-1, w

49 nto the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Ar

50 Treprostinil stimulates the engraftment of human and mur

51 ant intravenous epoprostenol or subcutaneous treprostinil therapy.

52 in part to the previously unknown ability of treprostinil to stimulate the EP2 receptor.

53 Treprostinil (TRE), a prostacyclin analogue with extende

54 0%) or sildenafil were randomized to inhaled treprostinil (up to 54 mug) or inhaled placebo 4 times d

55 Inhaled treprostinil was associated with an increase in 6MWD at

56 onists tested in combination with forskolin, treprostinil was most efficacious in raising intracellul

57 In the remaining 11 patients, inhaled treprostinil was safe and well tolerated.

58 Inhaled treprostinil was safe and well-tolerated.

59 Conclusions: Patients who received inhaled treprostinil were significantly less likely to experienc